Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea · Delayed Price · Currency is KRW 45,000
-1,800 (-3.85%)
Oct 10, 2025, 3:30 PM KST
Kolon TissueGene Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 5,493 | 5,073 | 3,706 | 9,456 | 4,003 | 3,556 | Upgrade | |
Revenue Growth (YoY) | 16.53% | 36.90% | -60.81% | 136.22% | 12.58% | 17.17% | Upgrade |
Cost of Revenue | 4,867 | 4,528 | 3,340 | 1,811 | 3,611 | 3,230 | Upgrade |
Gross Profit | 625.47 | 545.13 | 365.92 | 7,645 | 392.15 | 326 | Upgrade |
Selling, General & Admin | 15,508 | 15,849 | 13,679 | 14,694 | 15,906 | 24,355 | Upgrade |
Research & Development | 7,199 | 5,612 | 5,635 | 7,123 | 29,890 | 15,724 | Upgrade |
Other Operating Expenses | 340.19 | 269.39 | 173.93 | 224.81 | 56.02 | 250.31 | Upgrade |
Operating Expenses | 23,791 | 22,543 | 20,877 | 23,953 | 47,493 | 41,883 | Upgrade |
Operating Income | -23,166 | -21,998 | -20,511 | -16,308 | -47,101 | -41,557 | Upgrade |
Interest Expense | -81.37 | -89.85 | -285.82 | -371.18 | -466.46 | -835.26 | Upgrade |
Interest & Investment Income | 1,239 | 1,040 | 2,221 | 670.49 | 129.69 | 876.57 | Upgrade |
Currency Exchange Gain (Loss) | -1,430 | 813.15 | 256.82 | 1,512 | 50.89 | -69.97 | Upgrade |
Other Non Operating Income (Expenses) | -64,308 | -13,661 | 1,351 | 4,676 | 249.99 | -79.74 | Upgrade |
EBT Excluding Unusual Items | -87,746 | -33,895 | -16,968 | -9,821 | -47,136 | -41,665 | Upgrade |
Gain (Loss) on Sale of Assets | -0.24 | 1.02 | -3.43 | - | -14.87 | 0.5 | Upgrade |
Pretax Income | -87,746 | -33,894 | -16,971 | -9,821 | -47,151 | -41,665 | Upgrade |
Income Tax Expense | 55.54 | -95.47 | 253.15 | 1,316 | 218.27 | 123.68 | Upgrade |
Net Income | -87,801 | -33,799 | -17,224 | -11,136 | -47,370 | -41,788 | Upgrade |
Net Income to Common | -87,801 | -33,799 | -17,224 | -11,136 | -47,370 | -41,788 | Upgrade |
Shares Outstanding (Basic) | 80 | 77 | 72 | 66 | 61 | 61 | Upgrade |
Shares Outstanding (Diluted) | 80 | 77 | 72 | 66 | 61 | 61 | Upgrade |
Shares Change (YoY) | 7.73% | 7.32% | 8.18% | 8.25% | 0.29% | -0.06% | Upgrade |
EPS (Basic) | -1097.18 | -439.20 | -240.20 | -168.00 | -773.60 | -684.40 | Upgrade |
EPS (Diluted) | -1097.18 | -439.20 | -240.20 | -168.00 | -773.60 | -684.40 | Upgrade |
Free Cash Flow | -24,199 | -20,581 | -24,370 | -26,844 | -40,568 | -38,952 | Upgrade |
Free Cash Flow Per Share | -302.39 | -267.44 | -339.84 | -404.97 | -662.52 | -637.95 | Upgrade |
Gross Margin | 11.39% | 10.75% | 9.87% | 80.85% | 9.80% | 9.17% | Upgrade |
Operating Margin | -421.77% | -433.58% | -553.45% | -172.46% | -1176.59% | -1168.69% | Upgrade |
Profit Margin | -1598.56% | -666.19% | -464.76% | -117.77% | -1183.31% | -1175.21% | Upgrade |
Free Cash Flow Margin | -440.58% | -405.66% | -657.56% | -283.88% | -1013.40% | -1095.44% | Upgrade |
EBITDA | -22,431 | -21,189 | -19,099 | -14,643 | -45,550 | -39,914 | Upgrade |
EBITDA Margin | - | - | - | -154.85% | - | - | Upgrade |
D&A For EBITDA | 735.31 | 808.55 | 1,412 | 1,665 | 1,551 | 1,642 | Upgrade |
EBIT | -23,166 | -21,998 | -20,511 | -16,308 | -47,101 | -41,557 | Upgrade |
EBIT Margin | - | - | - | -172.46% | - | - | Upgrade |
Advertising Expenses | - | 37.32 | 11.48 | 0.5 | 18.66 | 68.88 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.